# KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

> **NCT01487174** · PHASE3 · TERMINATED · sponsor: **Kadmon Corporation, LLC** · enrollment: 8 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** KD019
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT01487174
- **Lead sponsor:** Kadmon Corporation, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12-14
- **Primary completion:** 2013-07-25
- **Final completion:** 2013-07-25
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Kadmon has made a business decision to terminate the study due to slow enrollment. Note the decision to terminate the study was not related to safety issues
- **Last updated:** 2022-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01487174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01487174, "KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01487174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*